ADXS - Advaxis, Inc.
| Previous Close | 0.3280 |
| Open | 0.3297 |
| Bid | 0.3285 x 2900 |
| Ask | 0.3300 x 3200 |
| Day's Range | 0.3202 - 0.3371 |
| 52 Week Range | 0.2050 - 10.8000 |
| Volume | 721,187 |
| Avg. Volume | 5,113,364 |
| Market Cap | 8.021M |
| Beta (3Y Monthly) | 4.23 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.0940 |
| Earnings Date | Jan 8, 2020 - Jan 13, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.65 |
- Business Wire
Advaxis and UCLA Enter Collaboration for Glioblastoma Immunotherapy Discovery Research
Advaxis, Inc. (ADXS), a clinical-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced a research collaboration agreement with the University of California Los Angeles (UCLA) to conduct preclinical studies evaluating the Company’s Lm technology in mouse tumor models of glioblastoma multiforme (GBM). Specifically, the collaboration with Dr. Vaithi Arumugaswami’s group at UCLA’s Department of Molecular and Medical Pharmacology will investigate anti-tumor immunity and anti-tumor responses generated by Lm vaccines that express diverse glioblastoma neoantigens.
- Business Wire
Advaxis Announces Updated Prolonged Survival Data in Phase 1/2 ADXS-PSA Trial
Advaxis, Inc. (ADXS), a clinical-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced updated median overall survival data from its Phase 1/2 KEYNOTE-046 study in metastatic, castration-resistant prostate cancer (mCRPC). This trial is being conducted in conjunction with Merck (known as MSD outside the U.S. and Canada) and is evaluating ADXS-PSA, one of Advaxis’ Listeria monocytogenes (Lm)-based immunotherapies, alone and in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy.
- Simply Wall St.
Is This A Catalyst To Buy Advaxis, Inc. (NASDAQ:ADXS)?
Trailing twelve-month data shows us that Advaxis, Inc.'s (NASDAQ:ADXS) earnings loss has accumulated to -US$25.0m...
- Benzinga
The Daily Biotech Pulse: Translate Bio Halts mRNA Therapy Trial, Roche Multiple Sclerosis Biomarker Data, D-Day For Xeris
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Sept. 9.) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ...
- Business Wire
Advaxis Reports Fiscal Third Quarter 2019 Financial Results and Provides Pipeline Update
Advaxis, Inc. , a clinical-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced an update on its clinical pipeline and financial results for the fiscal third quarter ended July 31, 2019.
- GlobeNewswire
BriaCell Appoints Richard J. Berman to Board of Directors
BERKELEY, Calif., and VANCOUVER, British Columbia, Aug. 12, 2019 -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage.
- Benzinga
The Daily Biotech Pulse: Jounce Jumps On Licensing Deal, Regulus Hit With Partial Clinical Hold, Genomic Health Added to S&P SmallCap Index
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 23) Akero Therapeutics Inc (NASDAQ: AKRO ) Mirum Pharmaceuticals ...
- Business Wire
Advaxis Announces Increasing Focus on Neoantigen-Directed Immunotherapies and Closing of Its Phase 3 AIM2CERV Study
Advaxis, Inc. (ADXS), a clinical-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that it is increasing its focus on neoantigen-directed immunotherapies and closing the AIM2CERV Phase 3 clinical trial with axalimogene filolisbac (AXAL) in high-risk locally advanced cervical cancer. Advaxis intends to continue to support the clinical development of AXAL, its single-antigen construct, in other HPV-related cancers while redirecting resources towards advancing its neoantigen-directed programs.
- Thomson Reuters StreetEvents
Edited Transcript of ADXS earnings conference call or presentation 11-Jun-19 3:00pm GMT
Q2 2019 Advaxis Inc Earnings Call
- ACCESSWIRE
Advaxis, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / June 11, 2019 / Advaxis, Inc. (NASDAQ: ADXS ) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on June 11, 2019 at 11:00 AM Eastern ...
- Business Wire
Advaxis Reports Second Quarter Fiscal 2019 Financial Results and Provides Pipeline Update
Conference call to be held June 11 at 11:00 a.m. ET
- Business Wire
Advaxis to Host Business Update Conference Call on June 11, 2019
Advaxis, Inc. (ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces that the company will host a business update call on Tuesday, June 11, 2019 at 11:00 a.m. ET. During the call, Advaxis’ senior management will review the company’s clinical development programs and recent financial results, and provide a general business update. The company intends to issue a news release summarizing financial results for the fiscal second quarter ended April 30, 2019 after market close on Monday, June 10, 2019.
- Simply Wall St.
What Kind Of Investor Owns Most Of Advaxis, Inc. (NASDAQ:ADXS)?
The big shareholder groups in Advaxis, Inc. (NASDAQ:ADXS) have power over the company. Large companies usually have...
- Benzinga
Advaxis Shares Climb After FDA Lifts Partial Clinical Hold On Cervical Cancer Drug
Nanocap Advaxis, Inc. (NASDAQ: ADXS ) is seeing strength Wednesday following an announcement concerning its cervical cancer drug. What Happened Advaxis announced the lifting of a partial clinical hold ...
- Business Wire
FDA Lifts Partial Clinical Hold on Phase 3 AIM2CERV Study of Axalimogene Filolisbac
Advaxis, Inc. (ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that the U.S. Food and Drug Administration (FDA or Agency) has lifted the partial clinical hold on AIM2CERV, the company’s Phase 3 clinical trial of axalimogene filolisbac (AXAL) for the treatment of patients with high-risk locally advanced cervical cancer. In its letter, the FDA acknowledged that the company satisfactorily addressed all hold questions. As announced on January 23, 2019, the FDA placed a partial clinical hold on this study relating to the Agency’s requests for additional information pertaining to certain AXAL chemistry, manufacturing and controls (CMC) matters. The Agency did not cite any safety issues related to the trial and all enrolled patients continued to receive treatment, per the trial protocol.
- Business Wire
Advaxis Announces Two Poster Presentations at the Frontiers in Cancer Immunotherapy Conference
Advaxis, Inc. (ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces the presentation of two posters at the Frontiers in Cancer Immunotherapy conference, being held today at the New York Academy of Sciences in New York City. Both posters were first presented at the recent American Association for Cancer Research (AACR) Annual Meeting, and each has updated findings being presented today. The first presentation regarding a poster entitled “Effects of ADXS-PSA With or Without Pembrolizumab on Survival and Antigen Spreading in Metastatic, Castration-Resistant Prostate Cancer Patients (Results from KEYNOTE-046)” is conference poster #31, and will be presented by Robert Petit, Ph.D., Advaxis Chief Scientific Officer, and Mark N. Stein, M.D., FACS, Associate Professor of Medical Oncology at Columbia University Medical Center, from 4:45 to 5:30 p.m. Eastern time.
- Business Wire
Advaxis Announces Appointment of Dr. Robert Petit to Chair of Scientific Advisory Board and Departure as Chief Scientific Officer
Advaxis, Inc. (ADXS) (the “Company”), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that Robert Petit, Ph.D. will be leaving his position as Chief Scientific Officer at the end of the month. Dr. Petit will assist the Company in transitioning his duties over the next several weeks, and will continue to support the Company as an advisor and consultant in his capacity as the new Chair of the Advaxis Scientific Advisory Board, effective June 3, 2019.
- Business Wire
Advaxis to Participate in Five Upcoming Industry Conferences
Advaxis, Inc. , a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces participation in f
- Zacks
Advaxis (ADXS) Stock Sinks As Market Gains: What You Should Know
Advaxis (ADXS) closed the most recent trading day at $3.29, moving -0.3% from the previous trading session.
- Zacks
QIAGEN Drives Molecular Diagnostics Suite With New Test Kit
QIAGEN (QGEN) introduces the FDA approved companion diagnostic test to help in guiding therapy in any cancer identification.
- Zacks
Twist Bioscience (TWST) Looks Good: Stock Adds 6.5% in Session
Twist Bioscience (TWST) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
